Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM

British Journal of Haematology, 05/14/2012

The addition of bortezomib to low dose cytarabine arabinoside (LDAC) in higher–risk myelodysplastic syndrome (MDS) may improve results obtained with LDAC alone, especially in patients with unfavourable karyotypes.

Print Article Summary Cat 2 CME Report